News

The FDA Office of Drug Evaluation III responded to the Company’s formal appeal filed in response to the Complete Response Letter (CRL) of July 27, 2012 to the

On June 25, 2014, Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principle goals; 1) initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones’

In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer’s disease, after 52 weeks of treatment.

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic

The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting two inflammatory mediators, proteins which play a key role in major autoimmune diseases. "This is

Qudexy XR and Topiramate Extended-Release Capsules are indicated as initial monotherapy in patients 10 years of age and older with partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

The study is designed to assess the safety and anti-pruritic efficacy of Nalbuphine ER tablets in about 360 hemodialysis patients to be enrolled in the US and Europe.

As part of the deal, GSK secured a license to use Codexis’ proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The license enables the

As part of the deal, Abbott will carve out the assets and transfer them to a new public company, New Mylan, organised in the Netherlands. After transfer of